What Konakion-MM Treats: Main Uses and Benefits

Konakion-MM (Phytomenadione) is commonly used to provide short-term symptomatic assistance for symptoms related to systemic imbalance. Its therapeutic use is applied across domains where additional symptomatic support is needed to manage excessive bleeding. The primary indications confirm its role in easing these distressing symptoms.

It is relevant in situations involving certain distressing symptoms across a few key areas: managing hemorrhage and bleeding caused by anticoagulant therapy, addressing symptoms linked to Vitamin K deficiency arising from various disorders, and prophylaxis (prevention) of bleeding in newborns. The medication helps address symptom clusters that may become intense or disruptive, particularly those that create noticeable physiological strain.

The primary patient benefit is the support it provides in reducing the overall burden of distressing bleeding manifestations. It may help patients cope more steadily with symptom fluctuations.

“The medication is applied in clinical settings that involve acute or unstable symptom patterns.”

Quick Fact: Relief for Bleeding Symptoms

Konakion-MM contributes to improved comfort and assists with maintaining functional stability during periods of heightened symptoms.

The eligibility for Konakion-MM (phytomenadione) is strictly governed by regulatory labeling, defining the populations who may use the medicine and those who must not.

Contraindicated Populations

The medicine is contraindicated and must not be used in any patient with a known hypersensitivity or allergy to the active substance phytomenadione or any other ingredients in the formulation.

Age-Related and Conditional Eligibility

Population Group	Regulatory Status
All Ages	Generally allowed for approved indications.
Neonates/Infants	Approved for VKDB prophylaxis/treatment, requiring the specific Paediatric formulation.
Elderly Patients	Considered more sensitive; use should be at the lower end of the recommended dose range.
Premature Infants (< 2.5 kg)	Parenteral use is restricted due to a documented increased risk of kernicterus.
Severe Liver Impairment	Requires careful monitoring of clotting status (INR).

Pregnancy and Lactation Status

Konakion-MM is not recommended for use in pregnant or nursing mothers solely for the prophylaxis of bleeding in the newborn, though therapeutic use for the mother may be permitted if the benefit is determined to outweigh potential risk.

Interactions with other medicines and products

The interaction profile for Konakion-MM (phytomenadione, Vitamin K1) is primarily characterized by its function as an antidote and specific procedural constraints during administration. Official regulatory information indicates that no other significant interactions are known beyond the product's primary pharmacodynamic role and technical incompatibilities.

---

Documented Pharmacodynamic Interactions

Konakion-MM exerts a potent antagonistic effect against coumarin-type anticoagulants, such as warfarin and phenindione. This is the key therapeutic interaction documented in official labeling.

Substances that May Interfere with Action

Certain medicinal products are noted for potentially interfering with the action of Vitamin K1 or affecting the body's Vitamin K status, which may necessitate careful monitoring or treatment with Konakion-MM. These include:

• Anticonvulsants (e.g., phenobarbital, phenytoin): Maternal use is noted as a risk factor for Vitamin K deficiency in neonates.
• Antibiotics: Certain long-term or broad-spectrum antibiotics may cause hypoprothrombinemia.
• Salicylates: Listed as a substance that may interfere with the way Vitamin K1 works.

---

Procedural Interaction Constraints

The Konakion-MM ampoule solution must not be diluted or mixed with other parenteral medications. However, the solution may be injected into the lower part of the infusion set (e.g., via a Y-site or 3-way tap) during continuous infusion of specific solutions, namely sodium chloride 0.9% or dextrose 5%.

How Konakion-MM Works: Mechanism of Action

Konakion-MM (Phytomenadione) is a synthetic form of Vitamin K1 that functions as an essential cofactor in specific liver and tissue processes. Its primary action involves participation in the Vitamin K Cycle within the liver, where it is required by the gamma-glutamyl carboxylase enzyme.

This enzyme facilitates the post-translational modification (gamma-carboxylation) of precursor proteins, specifically coagulation factors II, VII, IX, and X. This carboxylation step is necessary to convert these proteins into their fully functional, active forms, consequently increasing the pool of activated coagulation factors and influencing the dynamics of blood clot formation (hemostasis).

Separately, the same cofactor mechanism is necessary to activate non-coagulation proteins, such as osteocalcin, found in bone and other tissues. Engaging these mechanisms participates in the carboxylation of proteins required for calcium binding and the function of structural components in these systems.

How to Use Konakion-MM

Konakion-MM (Phytomenadione) is administered according to specific protocols, with the choice of administration route strictly dependent on the patient's condition and the urgency of required action.

Administration Routes and Technique

The medication is used via intravenous (IV) injection and oral administration. The IV route is primarily selected for rapidly addressing severe hemorrhage, while the oral route is suitable for non-severe scenarios. If administered intravenously, the injection must be given slowly, over a period of at least 30 seconds. For oral use, the required dose is measured from the ampoule solution and administered directly into the mouth. The intramuscular (IM) route is generally discouraged in adults at risk of bleeding due to variable absorption and potential for hematoma, but it is used for the prophylaxis of Vitamin K Deficiency Bleeding (VKDB) in newborns.

Official Dosing Patterns

The dosing range is highly variable and determined by the patient’s underlying condition and the degree of anticoagulation reversal needed. For adults experiencing severe or life-threatening hemorrhage, a dose of 5 mg to 10 mg is typically administered. For less severe situations, or asymptomatic high INR values, lower doses, such as 0.5 mg to 1.0 mg intravenously or orally, are used. A dose should not be repeated until the patient's coagulation status (e.g., INR) is monitored. If the initial dose has not adequately corrected the coagulation status, a repeat dose may be given 3 to 6 hours after the first.

Population-Specific Instructions

Specific dose patterns are noted for certain groups. Older adults may require a lower initial dose due to increased sensitivity, with the initial dose starting at the lower end of the dosing range. For newborns receiving VKDB prophylaxis, a dedicated 2 mg/0.2 ml concentration is used in multi-dose oral or single-dose IM regimens.

Preparation and Use Context

The solution for injection is generally used undiluted and must not be mixed with other parenteral solutions or infusions. The administration of Konakion-MM is typically a short-term, acute intervention and not a prolonged daily regimen.

Research evidence / Overview of studies for Konakion-MM

Research concerning Konakion-MM (phytomenadione) has been conducted to explore its use in clinical situations where systemic clotting factor imbalance may occur. Findings describe group patterns and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.

---

Evidence for Management of Excessive Warfarin Anticoagulation

Research was conducted to evaluate Konakion-MM in adult patients receiving anticoagulant therapy. Studies explored the effects of different doses and routes of administration, such as oral versus injection. The primary measure monitored in these Randomized Controlled Trials (RCTs) was the change in the International Normalized Ratio (INR) over defined time intervals. Additionally, research tracked clinical events such as the occurrence of major bleeding and potential risk of thrombotic events following the administration.

---

Evidence for Prevention and Treatment of Bleeding in Newborns

For newborns and infants, the evidence base includes large-scale Epidemiological Surveillance Systems and Clinical Trials. These studies compared the single intramuscular injection versus various multi-dose oral schedules. Outcomes monitored included the observed incidence of clinical bleeding and biochemical outcomes like the levels of PIVKA-II (a laboratory marker for Vitamin K status).

Epidemiological data research describes observed changes in the incidence of early and classic VKDB following the widespread use of preventative administration. Studies reported that a single intramuscular administration was associated with a measured shift in PIVKA-II, and evidence indicates this approach was explored in research as a preventative strategy.

---

What Research Gaps and Uncertainties Remain

Major Clinical Outcomes: Comparative evidence is lacking. The research base contains limited information from trials that directly compared the intervention to placebo or alternative strategies while examining a reduction in the risk of severe, patient-important bleeding events.

Long-Term Effects: Follow-up durations were limited in the reversal studies, and data shows there is limited information for long-term outcomes or the durability of the response outside the immediate correction window.

Key Studies & References

1. Konakion MM 10 mg/1 ml, solution for injection/oral administration (HPRA Licence - Irish Regulatory Document)

Common questions about Konakion-MM (FAQ)

---

Q: Can Konakion-MM be mixed with IV solutions, and if so, which ones?

Official regulatory documents advise that Konakion-MM solution should not be diluted or pre-mixed with other medications. However, the product information notes it may be administered via injection into the port of an existing infusion set. Specifically, 0.9% sodium chloride (saline) or 5% dextrose are the solutions noted in product information for this procedure.

---

Q: What is the recommended dose of Konakion-MM for a non-severe or high INR situation?

According to the official product information, small doses of Vitamin K1 (Konakion-MM), usually at the lower end of the recommended range, are generally used for non-severe situations. This includes cases where the International Normalized Ratio (INR) is high but there is little or no active bleeding. Official product information indicates these lower dose ranges are used to manage a high INR.

---

Q: What is the onset of action for Konakion-MM when given IV versus orally?

Konakion-MM is not expected to produce an immediate effect on clotting factors. Official product information indicates that after an intravenous (IV) injection, the medicine’s action is generally detectable within one to two hours. The effect on coagulation status is typically observed within 3 to 6 hours after administration.

---

Q: How does Konakion-MM affect patients who are also taking Coumadin (Warfarin)?

Konakion-MM is known to be a potent antagonist against coumarin-type anticoagulants, such as Warfarin. Its action works against the effects of these anticoagulant medicines. Regulatory information notes that if a patient needs to restart anticoagulant therapy, using a large dose of Konakion-MM may interfere with the process of reintroducing the medication.

---

Q: What happens if the Konakion-MM solution has been accidentally frozen?

Official storage instructions specify that Konakion-MM should be stored below 25 C and the regulatory guidance specifies that the solution must not be frozen. If the solution has been stored incorrectly, it should be checked before use. If it appears cloudy (turbid) or shows signs of phase separation, the official product information states that the solution must not be administered.

How to Store and Dispose of Konakion-MM

Official regulatory guidelines define specific conditions to maintain the stability and quality of Konakion-MM (Phytomenadione) solution.

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C (Do not freeze).
Protection	Keep in the original outer package to protect the solution from light.
Stability Check	The solution must be clear at the time of use. Do not use if the contents are turbid or show phase separation or if the expiry date has passed.
Child Safety	Keep the medicine out of the sight and reach of children.

Disposal Instructions

Dispose of unused or expired Konakion-MM by returning it to a pharmacist or healthcare professional for careful disposal. Do not dispose of the medicine through household waste, drains, or other non-regulated channels.